122 related articles for article (PubMed ID: 2027538)
1. Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa.
Nishi K; Kondo T; Narabayashi H
Neurosci Lett; 1991 Feb; 123(2):244-7. PubMed ID: 2027538
[TBL] [Abstract][Full Text] [Related]
2. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
3. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
4. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Sundström E; Fredriksson A; Archer T
Brain Res; 1990 Oct; 528(2):181-8. PubMed ID: 2271921
[TBL] [Abstract][Full Text] [Related]
5. MPTP-induced hypoactivity in mice: reversal by L-dopa.
Fredriksson A; Plaznik A; Sundström E; Jonsson G; Archer T
Pharmacol Toxicol; 1990 Oct; 67(4):295-301. PubMed ID: 2077520
[TBL] [Abstract][Full Text] [Related]
6. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice.
Rommelfanger KS; Edwards GL; Freeman KG; Liles LC; Miller GW; Weinshenker D
Proc Natl Acad Sci U S A; 2007 Aug; 104(34):13804-9. PubMed ID: 17702867
[TBL] [Abstract][Full Text] [Related]
7. Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA.
Melamed E; Rosenthal J; Globus M; Cohen O; Uzzan A
Brain Res; 1985 Sep; 342(2):401-4. PubMed ID: 3876139
[TBL] [Abstract][Full Text] [Related]
8. Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Shimazu S; Takahata K; Tamashiro A; Yoneda F; Iida Y; Saji H
J Neural Transm (Vienna); 2003 Aug; 110(8):871-83. PubMed ID: 12898343
[TBL] [Abstract][Full Text] [Related]
9. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
[TBL] [Abstract][Full Text] [Related]
10. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
11. A simple quantitative bradykinesia test in MPTP-treated mice.
Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
[TBL] [Abstract][Full Text] [Related]
12. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals.
Andrews AM; Ladenheim B; Epstein CJ; Cadet JL; Murphy DL
Mol Pharmacol; 1996 Dec; 50(6):1511-9. PubMed ID: 8967972
[TBL] [Abstract][Full Text] [Related]
13. Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists.
Fredriksson A; Palomo T; Chase T; Archer T
J Neural Transm (Vienna); 1999; 106(3-4):283-300. PubMed ID: 10392537
[TBL] [Abstract][Full Text] [Related]
14. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
Rozas G; López-Martín E; Guerra MJ; Labandeira-García JL
J Neurosci Methods; 1998 Sep; 83(2):165-75. PubMed ID: 9765130
[TBL] [Abstract][Full Text] [Related]
15. Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP): a comparative study with 2'-CH3-MPTP and MPTP.
Andrews AM; Murphy DL
J Neurochem; 1993 Mar; 60(3):1167-70. PubMed ID: 8094744
[TBL] [Abstract][Full Text] [Related]
16. Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine.
Luellen BA; Miller DB; Chisnell AC; Murphy DL; O'Callaghan JP; Andrews AM
J Pharmacol Exp Ther; 2003 Dec; 307(3):923-31. PubMed ID: 14561848
[TBL] [Abstract][Full Text] [Related]
17. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
[TBL] [Abstract][Full Text] [Related]
18. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.
Treseder SA; Jackson M; Jenner P
Br J Pharmacol; 2000 Apr; 129(7):1355-64. PubMed ID: 10742291
[TBL] [Abstract][Full Text] [Related]
19. Synergistic interactions between NMDA-antagonists and L-dopa on activity in MPTP-treated mice.
Fredriksson A; Gentsch C; Archer T
J Neural Transm Gen Sect; 1994; 97(3):197-209. PubMed ID: 7873129
[TBL] [Abstract][Full Text] [Related]
20. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity.
Battaglia G; Gesi M; Lenzi P; Busceti CL; Soldani P; Orzi F; Rampello L; Nicoletti F; Ruggieri S; Fornai F
Ann N Y Acad Sci; 2002 Jun; 965():254-66. PubMed ID: 12105101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
